Cipher Pharmaceuticals Provides CIP-TRAMADOL ER Regulatory Update

MISSISSAUGA, ON, Oct. 29 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) announced that it has been informed that additional time will be required for the U.S. Food and Drug Administration to complete its review of the Company's New Drug Application for CIP-TRAMADOL ER, an extended-release formulation of the analgesic tramadol. The Company previously disclosed that it expected the review to be completed by mid-October 2008.
MORE ON THIS TOPIC